Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YH0618 is a Traditional Chinese Medicine (TCM) herbal granule formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily investigated for the prevention and treatment of chemotherapy-induced alopecia (CIA) in patients with breast cancer. The formulation is based on TCM principles that link hair loss to kidney deficiency, and it aims to protect hair follicles and support renal function during chemotherapy. Clinical evaluation of YH0618 involves both Chinese and Western medical criteria to assess its efficacy in reducing hair loss and its impact on renal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on YH0618 (Guangdong Provincial Hospital of Traditional Chinese Medicine).